SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immuneering Corp Appoints Andrew Gengos As CFO

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16...

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

Equity

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.


Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...

Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

$IMRX Q3 &#39;26 Earnings Results &amp; Recap

Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.

Stocktwits

Immuneering Corp

 Q3 '26 Earnings Results & Recap

Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.

Immuneering shortened its cash runway guidance from 2029 to fourth quarter of 2028, reported higher Q3 R&D expense and net loss, and has not completed registrational trials or approved products.

Immuneering reported 17.3-month median survival, 36% overall response and 82% disease control in interim pancreatic-cancer data, with no Grade 5 events or new safety signals; MAPKeeper 301 enrollment was ahead of schedule.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Neutral Sentiment

<ul class="summary-bullets"><li>The selloff follows the company's presentation of updated early-stage data for its pancreatic cancer drug, atebimetinib, at the ASCO 2026 Annual Meeting.</li><li>The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients.</li><li>Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.</li></ul> Shares of Immuneering Corporation (IMRX) fell sharply on Monday, dropping about 23%, after the company presented updated early-stage data for its pancreatic cancer drug atebimetinib at the ASCO 2026 Annual Meeting.Despite the positive results, the stock slipped following a recent run-up in the stock. The stock closed up 14% on the last trading day but is now on track to record its worst day since early January, if losses hold.<h2 class="st-heading-2">IMRX’s Trial Data</h2>The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients. That is more than double the 8.5-month historical average for the standard chemotherapy alone. Median progression-free survival was 8.3 months, with an objective response rate of 36% and a disease control rate of 82%. The drug was generally well tolerated, with no major new safety issues reported.Both overall survival and median progression-free survival help doctors understand how well a cancer treatment is working. Overall survival (OS) is the length of time from the start of treatment until a patient dies from any cause, while median progression-free survival (PFS) measures the time from the start of treatment until the cancer worsens or the patient dies.Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.CEO Ben Zeskind said the results strengthen the company’s belief that atebimetinib could meaningfully improve outcomes for pancreatic cancer patients.<h2 class="st-heading-2">How Did IMRX Retail Traders React?</h2>On Stocktwits, retail sentiment around IMRX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user attributed the stock drop to a “sell the news” event.<stembedurl>https://www.stocktwits.com/stockymon/message/655020849</stembedurl>Another user cheered the “good results” and expressed optimism for the stock touching $6/ share this month.<stembedurl>https://www.stocktwits.com/CEM97/message/655018031</stembedurl>According to data from Koyfin, all six analysts covering IMRX rate it ‘Buy’ or higher. The average 12-month price target on the stock is $17, representing a potential upside of about 195% from last closing price.<a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> has gained over 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivn-stock-surges-as-r2-nears-delivery-kickoff/cZ0WRzjRevO">RIVN Stock Surges For 8th Straight Day: Rivian’s Rival To Tesla Model Y Nears June 9 Delivery Kickoff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Immuneering logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.75
Prev Close	$4.02
Open	$4.01
Dividend Yield	0.00%
50-Day Moving Average	$4.28
Beta	1.38
Avg. Volume	702,519.94
PE Ratio	-3.64

52-Week High	$8.48
52-Week Low	$3.38
Market Capitalization	$242.54M
EPS (Annual)	-$1.27
Price to Book	1.44
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMRX Fundamentals